The clinical and therapeutic implications of cancer stem cell biology

Expert Review of Anticancer Therapy

Volumn 11, Issue 7, 2011, Pages 1133-1145

  Cheng, Liang ^a   Alexander, Riley ^a   Zhang, Shaobo ^a   Pan, Chong Xian ^b   MacLennan, Gregory T ^c   Lopez Beltran, Antonio ^d   Montironi, Rodolfo ^e  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d UNIVERSITY OF CÓRDOBA   (Spain)

^e UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

cancer stem cell; mesenchymal stem cell; metastasis; pathway targeting; personalized medicine; targeted therapy; tumorigenesis

Indexed keywords

ALEMTUZUMAB; BCR ABL PROTEIN; CYCLOPAMINE; GEMTUZUMAB OZOGAMICIN; HERMES ANTIGEN; IMATINIB; LAPATINIB; MULTIDRUG RESISTANCE PROTEIN 1; ONCOPROTEIN; RITUXIMAB; SONIC HEDGEHOG PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENESIS; CELL ACTIVITY; CELL SURFACE; CHEMOSENSITIZATION; CHRONIC LYMPHATIC LEUKEMIA; CYTOLOGY; DRUG RESISTANCE; DRUG TARGETING; HUMAN; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; METASTASIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRECANCER; PROGNOSIS; RADIOSENSITIVITY; REVIEW; T CELL LYMPHOMA; TUMOR MICROENVIRONMENT;

EID: 79961074389     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.82     Document Type: Review

References (139)

1. Lapidot T, Sirard C, Vormoor J et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645-648 (1994). (Pubitemid 24067706)
2. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3, 730-737 (1997). (Pubitemid 27298715)
3. Sutherland HJ, Blair A, Zapf RW. Characterization of a hierarchy in human acute myeloid leukemia progenitor cells. Blood 87, 4754-4761 (1996). (Pubitemid 26162376)
4. Cox CV, Diamanti P, Evely RS et al. Expression of CD133 on leukemiainitiating cells in childhood ALL. Blood 113, 3287-3296 (2009).
5. Blair A, Hogge DE, Ailles LE et al. Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood 89, 3104-3112 (1997). (Pubitemid 27229792)
6. Jordan CT, Upchurch D, Szilvassy SJ et al. The interleukin-3 receptor a chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 14, 1777-1784 (2000).
7. Holyoake T, Jiang X, Eaves C et al. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 94, 2056-2064 (1999). (Pubitemid 29430422)
8. -bone marrow progenitor population in children with acute lymphoblastic leukemia. Blood 97, 3925-3930 (2001).
9. Matsui W, Huff CA, Wang Q et al. Characterization of clonogenic multiple myeloma cells. Blood 103, 2332-2336 (2004). (Pubitemid 38326254)
10. Al-Hajj M, Wicha MS, Benito-Hernandez A et al. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100, 3983-3988 (2003). (Pubitemid 36418143)
11. Stingl J, Eirew P, Ricketson I et al. Purification and unique properties of mammary epithelial stem cells. Nature 439, 993-997 (2006). (Pubitemid 43292419)
12. Singh SK, Clarke ID, Terasaki M et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 63, 5821-5828 (2003). (Pubitemid 37187480)
13. Singh SK, Hawkins C, Clarke ID et al. Identification of human brain tumour initiating cells. Nature 432, 396-401 (2004). (Pubitemid 39551674)
14. Higashi K, Ueda Y, Seki H et al. Fluorine- 18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J. Nucl. Med. 39, 1016-1020 (1998). (Pubitemid 28270118)
15. Collins AT, Berry PA, Hyde C et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 65, 10946-10951 (2005). (Pubitemid 41713363)
16. Hemmati HD, Nakano I, Lazareff JA et al. Cancerous stem cells can arise from pediatric brain tumors. Proc. Natl Acad. Sci. USA 100, 15178-15183 (2003). (Pubitemid 37518036)
17. O'Brien CA, Pollett A, Gallinger S et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445, 106-110 (2007). (Pubitemid 46067310)
18. Fang D, Nguyen TK, Leishear K et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 65, 9328-9337 (2005). (Pubitemid 41508000)
19. Collins AT, Maitland NJ. Prostate cancer stem cells. Eur. J. Cancer 42, 1213-1218 (2006). (Pubitemid 43795097)
20. Alvero AB, Chen R, Fu HH et al. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle 8, 158-166 (2009).
21. Takaishi S, Okumura T, Tu S et al. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 27, 1006-1020 (2009).
22. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N. Engl. J. Med. 355, 1253-1261 (2006). (Pubitemid 44427449)
23. Pan CX, Zhu W, Cheng L. Implications of cancer stem cells in the treatment of cancer. Future Oncol. 2, 723-731 (2006). (Pubitemid 44941990)
24. Haraguchi N, Utsunomiya T, Inoue H et al. Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 24, 506-513 (2006). (Pubitemid 44464754)
25. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT et al. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc. Natl Acad. Sci. USA 103, 11154-11159 (2006). (Pubitemid 44156488)
26. Dean M. Cancer stem cells: redefining the paradigm of cancer treatment strategies. Mol. Interv. 6, 140-148 (2006). (Pubitemid 43998812)
27. Cozzio A, Passegue E, Ayton PM et al. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev. 17, 3029-3035 (2003). (Pubitemid 38040767)
28. Bachoo RM, Maher EA, Ligon KL et al. Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 1, 269-277 (2002). (Pubitemid 41039151)
29. Cheng L, Zhang D. Molecular Genetic Pathology. Humana Press/Springer, NJ, USA (2008).
30. Reya T, Morrison SJ, Clarke MF et al. Stem cells, cancer and cancer stem cells. Nature 404, 105-111 (2001).
31. Quintana E, Shackleton M, Sabel MS et al. Efficient tumour formation by single human melanoma cells. Nature 456, 593-598 (2008).
32. Park SY, Lee HE, Li H et al. Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin. Cancer Res. 16, 876-887 (2010).
33. - fraction. Blood 115, 1976-1984 (2010).
34. Jordan CT, Guzman ML. Mechanisms controlling pathogenesis and survival of leukemic stem cells. Oncogene 23, 7178-7187 (2004). (Pubitemid 39382152)
35. Visvader JE. Cells of origin in cancer. Nature 469, 314-322 (2011).
36. Uchida N, Buck DW, He D et al. Direct isolation of human central nervous system stem cells. Proc. Natl Acad. Sci. USA 97, 14720-14725 (2000). (Pubitemid 32016642)
37. Collins AT, Habib FK, Maitland NJ et al. Identification and isolation of human prostate epithelial stem cells based on a(2) b(1)-integrin expression. J. Cell Sci. 114, 3865-3872 (2001). (Pubitemid 33094701)
38. Blair A, Sutherland HJ. Primitive acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo lack surface expression of c-kit (CD117).Exp. Hematol. 28, 660-671 (2000). (Pubitemid 30398523)
39. Molofsky AV, He S, Bydon M et al. Bmi-1 promotes neural stem cell self-renewal and neural development but not mouse growth and survival by repressing the p16Ink4a and p19Arf senescence pathways. Genes Dev. 19, 1432-1437 (2005). (Pubitemid 41003009)
40. Di Cristofano, APandolfi PP. The multiple roles of PTEN in tumor suppression. Cell 100, 387-390 (2000).
41. Yilmaz OH, Valdez R, Theisen BK et al. Pten dependence distinguishes haematopoietic stem cells from leukaemiainitiating cells. Nature 441, 475-482 (2006). (Pubitemid 44050144)
42. Hill R, Wu H. PTEN, stem cells, and cancer stem cells. J. Biol. Chem. 284, 11755-11759 (2009).
43. Shipitsin M, Campbell LL, Argani P et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 11, 259-273 (2007). (Pubitemid 46349843)
44. Chen L, Shen R, Ye Y et al. Precancerous stem cells have the potential for both benign and malignant differentiation. PLoS One 2, e293 (2007).
45. Gao JX. Cancer stem cells: the lessons from pre-cancerous stem cells. J. Cell. Mol. Med. 12, 67-96 (2008).
46. Houghton J, Stoicov C, Nomura S et al. Gastric cancer originating from bone marrow-derived cells. Science 306, 1568-1571 (2004). (Pubitemid 39564955)
47. Shen R, Ye Y, Chen L et al. Precancerous stem cells can serve as tumor vasculogenic progenitors. PLoS One 3, e1652 (2008).
48. Rangwala F, Omenetti A, Diehl AM. Cancer stem cells: repair gone awry? J. Oncol. 2011, 465343 (2011).
49. Mishra L, Banker T, Murray J et al. Liver stem cells and hepatocellular carcinoma. Hepatology 49, 318-329 (2009).
50. Bernards R, Weinberg RA. A progression puzzle. Nature 418, 823 (2002). (Pubitemid 34966286)
51. Balic M, Lin H, Young L et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin. Cancer Res. 12, 5615-5621 (2006). (Pubitemid 44629587)
52. Al-Hajj M, Wicha MS, Benito-Hernandez A et al. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100, 3983-3988 (2003). (Pubitemid 36418143)
53. Wicha MS. Cancer stem cells and metastasis: lethal seeds. Clin. Cancer Res. 12, 5606-5607 (2006). (Pubitemid 44629584)
54. Ponti D, Costa A, Zaffaroni N et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/ progenitor cell properties. Cancer Res. 65, 5506-5511 (2005). (Pubitemid 40911148)
55. Schabath H, Runz S, Joumaa S et al. CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells. J. Cell Sci. 119, 314-325 (2006). (Pubitemid 43210700)
56. Jones TD, Eble JN, Wang M et al. Molecular genetic evidence for the independent origin of multifocal papillary tumors in patients with papillary renal cell carcinomas. Clin. Cancer Res. 11, 7226-7233 (2005). (Pubitemid 41507679)
57. Jones TD, Carr MD, Eble JN et al. Clonal origin of lymph node metastases in bladder carcinoma. Cancer 104, 1901-1910 (2005). (Pubitemid 41513173)
58. Kernek KM, Ulbright TM, Zhang S et al. Identical allelic losses in mature teratoma and other histologic components of malignant mixed germ cell tumors of the testis. Am. J. Pathol. 163, 2477-2484 (2003). (Pubitemid 37466488)
59. Karhadkar SS, Bova GS, Abdallah N et al. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 431, 707-712 (2004). (Pubitemid 39382619)
60. + cancer stem ells with metastatic capacity in human colorectal cancer. Cell Stem Cell 6, 603-615 (2010).
61. Lang JE, Hall CS, Singh B et al. Significance of micrometastasis in bone marrow and blood of operable breast cancer patients: research tool or clinical application? Expert Rev. Anticancer Ther. 7, 1463-1472 (2007). (Pubitemid 351826911)
62. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat. Med. 12, 895-904 (2006). (Pubitemid 44175140)
63. Li F, Tiede B, Massague J et al. Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res. 17, 3-14 (2007). (Pubitemid 46096419)
64. Griffiths EA, Pritchard SA, Welch IM et al. Is the hypoxia-inducible factor pathway important in gastric cancer? Eur. J. Cancer 41, 2792-2805 (2005). (Pubitemid 41713116)
65. Muller A, Homey B, Soto H et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50-56 (2001). (Pubitemid 32225831)
66. Kaplan RN, Psaila B, Lyden D. Niche-toniche migration of bone-marrow-derived cells. Trends Mol. Med. 13, 72-81 (2007).
67. Abbott BL. ABCG2 (BCRP): a cytoprotectant in normal and malignant stem cells. Clin. Adv. Hematol. Oncol. 4, 63-72 (2006). (Pubitemid 43173716)
68. Scharenberg CW, Harkey MA, Torok- Storb B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 99, 507-512 (2002). (Pubitemid 34533085)
69. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 5, 275-284 (2005). (Pubitemid 40488633)
70. Belpomme D, Gauthier S, Pujade-Lauraine E et al. Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma. Ann. Oncol. 11, 1471-1476 (2000).
71. List AF, Kopecky KJ, Willman CL et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 98, 3212-3220 (2001).
72. Eyler CE, Rich JN. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J. Clin. Oncol. 26, 2839-2845 (2008).
73. Bao S, Wu Q, McLendon RE et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756-760 (2006). (Pubitemid 44949604)
74. Hadjihannas MV, Bruckner M, Jerchow B et al. Aberrant Wnt/β-catenin signaling can induce chromosomal instability in colon cancer. Proc. Natl Acad. Sci. USA 103, 10747-10752 (2006). (Pubitemid 44078047)
75. Ho MM, Ng AV, Lam S et al. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 67, 4827-4833 (2007). (Pubitemid 46910191)
76. Chapuy B, Koch R, Radunski U et al. Intracellular ABC transporter A3 confers multidrug resistance in leukemia cells by lysosomal drug sequestration. Leukemia (2008).
77. Rich JN. Cancer stem cells in radiation resistance. Cancer Res. 67, 8980-8984 (2007). (Pubitemid 47535877)
78. Tang C, Ang BT, Pervaiz S. Cancer stem cell: target for anti-cancer therapy. FSEB J. 21, 3777-3785 (2007). (Pubitemid 350232335)
79. Maitland NJ, Collins AT. Prostate cancer stem cells: a new target for therapy. J. Clin. Oncol. 26, 2862-2870 (2008).
80. + cells to blame? Breast Cancer Res. 12, 105 (2011).
81. Eyler CE, Rich JN. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J. Clin. Oncol. 26, 2839-2845 (2008).
82. Calabrese C, Poppleton H, Kocak M et al. A perivascular niche for brain tumor stem cells. Cancer Cell 11, 69-82 (2007). (Pubitemid 46054518)
83. Blagosklonny MV. Why therapeutic response may not prolong the life of a cancer patient: selection for oncogenic resistance. Cell Cycle 4, 1693-1698 (2005). (Pubitemid 41827304)
84. Zeppernick F, Ahmadi R, Campos B et al. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin. Cancer Res. 14, 123-129 (2008). (Pubitemid 351377986)
85. + cells. Blood 103, 3167-3174 (2004). (Pubitemid 38451695)
86. Graham SM, Jorgensen HG, Allan E et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99, 319-325 (2002).
87. Holtz MS, Slovak ML, Zhang F et al. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 99, 3792-3800 (2002). (Pubitemid 34534553)
88. Copland M, Hamilton A, Elrick LJ et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 107, 4532-4539 (2006). (Pubitemid 43801382)
89. Ihara A, Wada K, Yoneda M et al. Blockade of leukotriene B4 signaling pathway induces apoptosis and suppresses cell proliferation in colon cancer. J. Pharmacol. Sci. 103, 24-32 (2007). (Pubitemid 46175592)
90. Konig J, Hartel M, Nies AT et al. Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma. Int. J. Cancer 115, 359-367 (2005). (Pubitemid 40663738)
91. Cole SP, Bhardwaj G, Gerlach JH et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258, 1650-1654 (1992). (Pubitemid 23012438)
92. Doyle LA, Yang W, Abruzzo LV et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl Acad. Sci. USA 95, 15665-15670 (1998). (Pubitemid 29018757)
93. Peters-Golden M, Henderson WR Jr. Leukotrienes. N. Engl. J. Med. 357, 1841-1854 (2007).
94. Chen Y, Hu Y, Zhang H et al. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat. Genet. 41, 783-792 (2009).
95. Huss WJ, Gray DR, Greenberg NM et al. Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells. Cancer Res. 65, 6640-6650 (2005). (Pubitemid 41060700)
96. Mahon FX, Belloc F, Lagarde V et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 101, 2368-2373 (2003). (Pubitemid 36304670)
97. + cells. Br. J. Haematol. 118, 521-534 (2002). (Pubitemid 34994658)
98. Mohrin M, Bourke E, Alexander D et al. Hematopoietic stem cell quiescence promotes error-prone DNA repair and mutagenesis. Cell Stem Cell 7, 174-185 (2010).
99. Kvinlaug BT, Huntly BJ. Targeting cancer stem cells. Expert Opin. Ther. Targets 11, 915-927 (2007). (Pubitemid 47061315)
100. Ailles LE, Weissman IL. Cancer stem cells in solid tumors. Curr. Opin. Biotechnol. 18, 460-466 (2007). (Pubitemid 350116595)
101. Lichtman MA. Differentiation versus maturation of neoplastic hematopoietic cells: an important distinction. Blood Cells Mol. Dis. 27, 649-652 (2001). (Pubitemid 32757060)
102. Bernstein ID. Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate. Leukemia 14, 474-475 (2000). (Pubitemid 30142874)
103. Sievers EL, Larson RA, Stadtmauer EA et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J. Clin. Oncol. 19, 3244-3254 (2001). (Pubitemid 32591442)
104. Pagel JM, Appelbaum FR, Eary JF et al. 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood 107, 2184-2191 (2006). (Pubitemid 43289405)
105. Hu Y, Swerdlow S, Duffy TM et al. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc. Natl Acad. Sci. USA 103, 16870-16875 (2006). (Pubitemid 44737345)
106. McCubrey JA, Steelman LS, Abrams SL et al. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 22, 708-722 (2008). (Pubitemid 351565619)
107. Zhou H, Kim YS, Peletier A et al. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2- overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. Int. J. Radiat. Oncol. Biol. Phys. 58, 344-352 (2004). (Pubitemid 38142458)
108. Druker BJ, Tamura S, Buchdunger E et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2, 561-566 (1996).
109. Druker BJ, Sawyers CL, Kantarjian H et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038-1042 (2001). (Pubitemid 32267973)
110. Li X, Lewis MT, Huang J et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl Cancer Inst. 100, 672-679 (2008).
111. Kim PS, Lee PP, Levy D. Dynamics and potential impact of the immune response to chronic myelogenous leukemia. PLoS Comput. Biol. 4, e1000095 (2008).
112. Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat. Immunol. 5, 738-743 (2004). (Pubitemid 39023306)
113. Stingl J, Caldas C. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat. Rev. Cancer 7, 791-799 (2007). (Pubitemid 47463670)
114. Schulenburg A, Ulrich-Pur H, Thurnher D et al. Neoplastic stem cells: a novel therapeutic target in clinical oncology. Cancer 107, 2512-2520 (2006). (Pubitemid 44748537)
115. Jin Y, Lu Z, Ding K et al. Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kB pathway and generation of reactive oxygen species. Cancer Res. 70, 2516-2527 (2010).
116. Guzman ML, Jordan CT. Considerations for targeting malignant stem cells in leukemia. Cancer Control 11, 97-104 (2004). (Pubitemid 38596194)
117. Gupta PB, Onder TT, Jiang G et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138, 645-659 (2009).
118. Chen JK, Taipale J, Cooper MK et al. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev. 16, 2743-2748 (2002). (Pubitemid 35253140)
119. Chen JK, Taipale J, Young KE et al. Small molecule modulation of Smoothened activity. Proc. Natl Acad. Sci. USA 99, 14071-14076 (2002). (Pubitemid 35257626)
120. Schugar RC, Robbins PD, Deasy BM. Small molecules in stem cell self-renewal and differentiation. Gene Ther. 15, 126-135 (2008).
121. Cairns J. Somatic stem cells and the kinetics of mutagenesis and carcinogenesis. Proc. Natl Acad. Sci. USA 99, 10567-10570 (2002).
122. Park Y, Gerson SL. DNA repair defects in stem cell function and aging. Annu. Rev. Med. 56, 495-508 (2005). (Pubitemid 40299795)
123. Spradling A, Drummond-Barbosa D, Kai T. Stem cells find their niche. Nature 414, 98-104 (2001). (Pubitemid 33041633)
124. Lin H. The stem-cell niche theory: lessons from flies. Nat. Rev. Genet. 3, 931-940 (2002). (Pubitemid 35423505)
125. Rockey DC, Paulson E, Niedzwiecki D et al. Analysis of air contrast barium enema, computed tomographic colonography, and colonoscopy: prospective comparison. Lancet 365, 305-311 (2005). (Pubitemid 40139107)
126. Li L, Neaves WB. Normal stem cells and cancer stem cells: the niche matters. Cancer Res. 66, 4553-4557 (2006).
127. Sheu CC, Yu YP, Tsai JR et al. Development of a membrane array-based multimarker assay for detection of circulating cancer cells in patients with non-small cell lung cancer. Int. J. Cancer 119, 1419-1426 (2006).
128. Riethdorf S, Muller V, Zhang L et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin. Cancer Res. 16, 2634-2645 (2011).
129. Schuster R, Bechrakis NE, Stroux A et al. Circulating tumor cells as prognostic factor for distant metastases and survival in patients with primary uveal melanoma. Clin. Cancer Res. 13, 1171-1178 (2007). (Pubitemid 46424057)
130. Hess KR, Varadhachary GR, Taylor SH et al. Metastatic patterns in adenocarcinoma. Cancer 106, 1624-1633 (2006).
131. Karnoub AE, Dash AB, Vo AP et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449, 557-563 (2007). (Pubitemid 47525152)
132. Sneddon JB, Werb Z. Location, location, location: the cancer stem cell niche. Cell Stem Cell 1, 607-611 (2007). (Pubitemid 350215340)
133. Adams GB, Chabner KT, Alley IR et al. Stem cell engraftment at the endosteal niche is specified by the calciumsensing receptor. Nature 439, 599-603 (2006). (Pubitemid 43185384)
134. Borovski T, De Sousa EMF, Vermeulen L et al. Cancer stem cell niche: the place to be. Cancer Res. 71, 634-639 (2011).
135. Gilbertson RJ, Rich JN. Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat. Rev. Cancer 7, 733-736 (2007). (Pubitemid 47463683)
136. Yang ZJ, Wechsler-Reya RJ. Hit 'em where they live: targeting the cancer stem cell niche. Cancer Cell 11, 3-5 (2007).
137. de Groot JF, Fuller G, Kumar AJ et al. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro. Oncol. 12, 233-242 (2010).
138. Liu H, Patel MR, Prescher JA et al. Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models. Proc. Natl Acad. Sci. USA 107, 18115-18120 (2011).
139. Fuchs E, Tumbar T, Guasch G. Socializing with the neighbors: stem cells and their niche. Cell 116, 769-778 (2004). (Pubitemid 38410723)